Literature DB >> 21415306

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibition by 4-hydroxynonenal leads to increased Akt activation in hepatocytes.

Colin T Shearn1, Rebecca L Smathers, Benjamin J Stewart, Kristofer S Fritz, James J Galligan, Numsen Hail, Dennis R Petersen.   

Abstract

The production of reactive aldehydes such as 4-hydroxynonenal (4-HNE) is proposed to be an important factor in the etiology of alcoholic liver disease. To understand the effects of 4-HNE on homeostatic signaling pathways in hepatocytes, cellular models consisting of the human hepatocellular carcinoma cell line (HepG2) and primary rat hepatocytes were evaluated. Treatment of both HepG2 cells and primary hepatocytes with subcytotoxic concentrations of 4-HNE resulted in the activation of Akt within 30 min as demonstrated by increased phosphorylation of residues Ser473 and Thr308. Quantification and subsequent immunocytochemistry of phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P(3)[rsqb] resulted in a 6-fold increase in total PtdIns(3,4,5)P(3) and increased immunostaining at the plasma membrane after 4-HNE treatment. Cotreatment of HepG2 cells with 4-HNE and the phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (Ly294002) or the protein phosphatase 2A (PP2A) inhibitor okadaic acid revealed that the mechanism of activation of Akt is PI3K-dependent and PP2A-independent. Using biotin hydrazide detection, it was established that the incubation of HepG2 cells with 4-HNE resulted in increased carbonylation of the lipid phosphatase known as "phosphatase and tensin homolog deleted on chromosome 10" (PTEN), a key regulator of Akt activation. Activity assays both in HepG2 cells and recombinant PTEN revealed a decrease in PTEN lipid phosphatase activity after 4-HNE application. Mass spectral analysis of 4-HNE-treated recombinant PTEN detected a single 4-HNE adduct. Subsequent analysis of Akt dependent physiological consequences of 4-HNE in HepG2 cells revealed significant increases in the accumulation of neutral lipids. These results provide a potential mechanism of Akt activation and cellular consequences of 4-HNE in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415306      PMCID: PMC3102545          DOI: 10.1124/mol.110.069534

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase.

Authors:  David L Carbone; Jonathan A Doorn; Zachary Kiebler; Dennis R Petersen
Journal:  Chem Res Toxicol       Date:  2005-08       Impact factor: 3.739

2.  In situ detection of lipid peroxidation by-products in chronic liver diseases.

Authors:  V Paradis; M Kollinger; M Fabre; A Holstege; T Poynard; P Bedossa
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

3.  4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 2E1 in PC12 cells.

Authors:  Haider Raza; Annie John
Journal:  Toxicol Appl Pharmacol       Date:  2006-06-07       Impact factor: 4.219

4.  Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion.

Authors:  Young-Mi Go; Patrick J Halvey; Jason M Hansen; Matt Reed; Jan Pohl; Dean P Jones
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

5.  Experimental liver cirrhosis induced by alcohol and iron.

Authors:  H Tsukamoto; W Horne; S Kamimura; O Niemelä; S Parkkila; S Ylä-Herttuala; G M Brittenham
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Cytotoxic aldehydes originating from the peroxidation of liver microsomal lipids. Identification of 4,5-dihydroxydecenal.

Authors:  A Benedetti; M Comporti; R Fulceri; H Esterbauer
Journal:  Biochim Biophys Acta       Date:  1984-02-09

Review 7.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

Authors:  H Esterbauer; R J Schaur; H Zollner
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

8.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

9.  Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells.

Authors:  Barbara Dozza; Mark A Smith; George Perry; Massimo Tabaton; Paola Strocchi
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

10.  Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal.

Authors:  W Liu; A A Akhand; K Takeda; Y Kawamoto; M Itoigawa; M Kato; H Suzuki; N Ishikawa; I Nakashima
Journal:  Cell Death Differ       Date:  2003-07       Impact factor: 15.828

View more
  31 in total

Review 1.  Protein carbonylation and metabolic control systems.

Authors:  Jessica M Curtis; Wendy S Hahn; Eric K Long; Joel S Burrill; Edgar A Arriaga; David A Bernlohr
Journal:  Trends Endocrinol Metab       Date:  2012-06-27       Impact factor: 12.015

Review 2.  Protein carbonylation, mitochondrial dysfunction, and insulin resistance.

Authors:  Brigitte I Frohnert; David A Bernlohr
Journal:  Adv Nutr       Date:  2013-03-01       Impact factor: 8.701

3.  Increased hepatocellular protein carbonylation in human end-stage alcoholic cirrhosis.

Authors:  C T Shearn; D J Orlicky; L M Saba; A H Shearn; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2015-10-27       Impact factor: 7.376

4.  Temporally controlled targeting of 4-hydroxynonenal to specific proteins in living cells.

Authors:  Xinqiang Fang; Yuan Fu; Marcus J C Long; Joseph A Haegele; Eva J Ge; Saba Parvez; Yimon Aye
Journal:  J Am Chem Soc       Date:  2013-09-18       Impact factor: 15.419

5.  Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway.

Authors:  Mao Mao; Varadarajan Sudhahar; Kristine Ansenberger-Fricano; Denise C Fernandes; Leonardo Y Tanaka; Tohru Fukai; Francisco R M Laurindo; Ronald P Mason; Jeannette Vasquez-Vivar; Richard D Minshall; Krisztian Stadler; Marcelo G Bonini
Journal:  Free Radic Biol Med       Date:  2011-10-07       Impact factor: 7.376

Review 6.  4-Hydroxy-nonenal-A Bioactive Lipid Peroxidation Product.

Authors:  Rudolf J Schaur; Werner Siems; Nikolaus Bresgen; Peter M Eckl
Journal:  Biomolecules       Date:  2015-09-30

Review 7.  4-hydroxynonenal-mediated signaling and aging.

Authors:  Hongqiao Zhang; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2016-11-20       Impact factor: 7.376

8.  Role of physiological levels of 4-hydroxynonenal on adipocyte biology: implications for obesity and metabolic syndrome.

Authors:  Kalavathi Dasuri; Philip Ebenezer; Sun Ok Fernandez-Kim; Le Zhang; Zhanguo Gao; Annadora J Bruce-Keller; Linnea R Freeman; Jeffrey N Keller
Journal:  Free Radic Res       Date:  2012-10-16

9.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

10.  Modulation of keratinocyte expression of antioxidants by 4-hydroxynonenal, a lipid peroxidation end product.

Authors:  Ruijin Zheng; Diane E Heck; Vladimir Mishin; Adrienne T Black; Michael P Shakarjian; Ah-Ng Tony Kong; Debra L Laskin; Jeffrey D Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2014-01-11       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.